Table 3 Association of baseline characteristics and response parameters with the probability of achieving major histopathologic response
Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
N | % | OR | 95% CI | p | OR | 95% CI | p | |
Baseline characteristics | ||||||||
Sex | ||||||||
Male | 97 | 23.7 | 1 | — | — | — | — | — |
Female | 62 | 29.0 | 1.32 | 0.64–2.71 | 0.454 | — | — | — |
Time to metastases | ||||||||
Synchronous | 131 | 25.2 | 1 | — | — | — | — | — |
Metachronous | 28 | 28.6 | 1.88 | 0.48–2.95 | 0.708 | — | — | — |
No. of liver metastases | ||||||||
≥4 | 59 | 27.1 | 1 | — | — | — | — | — |
<4 | 74 | 28.4 | 1.06 | 0.50–2.29 | 0.862 | — | — | — |
Primary resected | ||||||||
No | 38 | 36.8 | 1 | — | — | — | — | — |
Yes | 120 | 22.5 | 0.50 | 0.23–1.09 | 0.079 | — | — | — |
Location of primary | ||||||||
Right colon | 40 | 27.5 | 1 | — | — | — | — | — |
Left colon | 116 | 25.0 | 0.88 | 0.39–1.98 | 0.752 | — | — | — |
Tumour size, diameter | ||||||||
>5 cm | 56 | 32.1 | 1 | — | — | — | — | — |
≤5 cm | 102 | 22.5 | 0.61 | 0.30–1.27 | 0.188 | — | — | — |
Distribution of liver metastases | ||||||||
Bilobar | 96 | 19.8 | 1 | — | — | — | — | — |
Unilobar | 54 | 29.6 | 1.71 | 0.79–3.69 | 0.171 | — | — | — |
No. of involved segments | ||||||||
>6 | 14 | 35.7 | 1 | — | — | — | — | — |
≤6 | 121 | 27.3 | 0.68 | 0.21–2.16 | 0.536 | — | — | — |
Disease-free interval | ||||||||
<12 mos | 22 | 22.7 | 1 | — | — | — | — | — |
>12 mos | 137 | 26.3 | 1.21 | 0.42–3.52 | 0.729 | — | — | — |
Mutational status | ||||||||
All wt | 91 | 19.8 | 1 | — | — | — | — | — |
RAS mut | 54 | 25.9 | 1.42 | 0.64–3.15 | 0.390 | — | — | — |
BRAF mut | 6 | 33.3 | 2.03 | 0.34–11.95 | 0.600 | — | — | — |
Targeted agent | ||||||||
Cetuximab | 56 | 14.3 | 1 | — | — | 1 | — | — |
Bevacizumab | 103 | 32.0 | 2.83 | 1.20–6.65 | 0.015 | 6.00 | 1.96–18.40 | 0.002 |
Chemotherapy backbone | ||||||||
COI | 67 | 14.9 | 1 | — | — | 1 | — | — |
FOLFOXIRI | 92 | 33.7 | 2.90 | 1.30–6.44 | 0.008 | 0.62 | 0.14–2.64 | 0.516 |
Response parameters | ||||||||
RECIST response | ||||||||
No | 24 | 16.7 | 1 | — | — | — | — | — |
Yes | 135 | 27.4 | 1.89 | 0.60–5.89 | 0.267 | — | — | — |
Early tumour shrinkage | ||||||||
No | 23 | 13.0 | 1 | — | — | — | — | — |
Yes | 126 | 28.6 | 2.67 | 0.75–9.53 | 0.119 | — | — | — |
Deepness of response (per 10% increase) | 121 | — | 1.31 | 1.07–1.60 | 0.009 | 1.52 | 1.38–1.94 | <0.001 |
